FDA Approves Olutasidenib for Relapsed or Refractory AML with a Susceptible IDH1 Mutation

December 2, 2022

For more information read the FDA announcement and the Rigel announcement.

Upcoming Events

ACCC 43rd National Oncology Conference

In Person October 21, 2026 at 8:00 AM EDT450 Summer St, Boston, MA 02210, USAOmni Boston Hotel at the Seaport, Boston

ACCC Oncology Reimbursement Meeting | Reno

In Person November 4, 2026 at 8:00 AM EST255 North Virginia Street, Reno, NV, USAWhitney Peak Hotel Reno, Tapestry Collection by Hilton,

ACCC Oncology Reimbursement Meeting | Providence

In Person November 10, 2026 at 8:00 AM EST5 Avenue of the Arts, Providence, RI, USARenaissance Providence Downtown Hotel,

Oncology

MSOS 2026 Bozeman Meeting

In Person Meeting & NetworkingSeptember 22, 2026 at 5:30 PM EDT5 W Mendenhall St suite 102, Bozeman, MT 59715, USA Urban Kitchen, Bozeman

Oncology

MSCO 2026 Fall Conference

In Person Conference & ConventionSeptember 22, 2026 at 5:00 PM CDT1500 Park Pl Blvd, Minneapolis, MN, USADoubleTree by Hilton Hotel Minneapolis - Park Place, Minneapolis

Oncology

HSCO 2026 September Dinner Symposium

In Person Conference & ConventionSeptember 23, 2026 at 5:30 PM HST3660 Waialae Ave, Honolulu, HI, USA3660 On The Rise, Honolulu

Oncology

RIOS Fall Meeting

In Person Conference & ConventionSeptember 25, 2026 at 5:30 PM EDT139 Mathewson Street, Providence, RI, USAHotel Providence, Providence

Oncology

Yellowstone Best of ASCO 2026 Presented By ISCO/MSOS/WSOS

In Person Conference & ConventionOctober 2, 2026 at 6:00 PM MDT400 E Snow King Ave, Jackson, WY, USASnow King Resort, Jackson

Oncology

IOS 2026 Oncology Practice Summit

In Person Conference & ConventionOctober 3, 2026 at 7:30 AM EDT8787 Keystone Crossing, Indianapolis, IN, USASheraton Indianapolis Hotel at Keystone Crossing, Indianapolis

Oncology

MOS 2026 Fall Conference

In Person Conference & ConventionOctober 6, 2026 at 5:15 PM CDT7730 Bonhomme Avenue, Clayton, St. Louis, MO, USALe Méridien St. Louis Clayton, Clayton

Trending Now on
ACCCBuzz Blog

Decentralized Clinical Trials in Community Oncology: Advancing Access Requires More Than Technology

Decentralized clinical trial approaches, including remote consent, telehealth, local laboratory and imaging services, and more, can help reduce some of the many barriers that prevent eligible patients from participating in trials. But as the participants in ACCC’s Advancing Decentralized Clinical Trials in the Community Setting Roundtable Series emphasized, implementing DCT elements is not simply a matter of adopting new technology. Doing so successfully requires thoughtful workflows and oversight structures that consider equity, scalability, and sustainability.

Highlights From Volume 41, Number 4 Oncology Issues

From precision medicine to psychosocial care to navigation for a diverse population, the latest issue Oncology Issues brings insights into not just institutional and administrative barriers to treatment, but areas of care that directly impact the lived experience of those navigating the cancer care continuum.

FDA Approves Olutasidenib for Relapsed or Refractory AML with a Susceptible IDH1 Mutation

Upcoming Events

ACCC 43rd National Oncology Conference

ACCC Oncology Reimbursement Meeting | Reno

ACCC Oncology Reimbursement Meeting | Providence

MSOS 2026 Bozeman Meeting

MSCO 2026 Fall Conference

HSCO 2026 September Dinner Symposium

RIOS Fall Meeting

Yellowstone Best of ASCO 2026 Presented By ISCO/MSOS/WSOS

IOS 2026 Oncology Practice Summit

MOS 2026 Fall Conference

Trending Now on
ACCCBuzz Blog

Decentralized Clinical Trials in Community Oncology: Advancing Access Requires More Than Technology

Highlights From Volume 41, Number 4 Oncology Issues

Transforming Access to Care Through Pre-Intake Navigation

An APP-Led Outpatient Bispecific Antibody Clinic

Recently Heard on
CANCER BUZZ Podcast

Embedding Local Expertise in Rural Cancer Prevention - Podcast [Ep. 241]

From Reactive to Proactive: Improving Access to Cancer Care Through Pre-Intake Navigation - [Podcast] Ep. 240

Real-World Oncology Decentralized Trials - [Video Podcast] Ep. 66

The Real Cost of Cancer: Financial Toxicity, Transportation Challenges, and Access Gaps – [Video Podcast] Ep. 65

Latest from Oncology Issues

Join the Conversation

FDA Approves Olutasidenib for Relapsed or Refractory AML with a Susceptible IDH1 Mutation

Upcoming Events

ACCC 43rd National Oncology Conference

ACCC Oncology Reimbursement Meeting | Reno

ACCC Oncology Reimbursement Meeting | Providence

MSOS 2026 Bozeman Meeting

MSCO 2026 Fall Conference

HSCO 2026 September Dinner Symposium

RIOS Fall Meeting

Yellowstone Best of ASCO 2026 Presented By ISCO/MSOS/WSOS

IOS 2026 Oncology Practice Summit

MOS 2026 Fall Conference

Trending Now on ACCCBuzz Blog

Decentralized Clinical Trials in Community Oncology: Advancing Access Requires More Than Technology

Highlights From Volume 41, Number 4 Oncology Issues

Transforming Access to Care Through Pre-Intake Navigation

An APP-Led Outpatient Bispecific Antibody Clinic

Recently Heard on CANCER BUZZ Podcast

Embedding Local Expertise in Rural Cancer Prevention - Podcast [Ep. 241]

From Reactive to Proactive: Improving Access to Cancer Care Through Pre-Intake Navigation - [Podcast] Ep. 240

Real-World Oncology Decentralized Trials - [Video Podcast] Ep. 66

The Real Cost of Cancer: Financial Toxicity, Transportation Challenges, and Access Gaps – [Video Podcast] Ep. 65

Latest from Oncology Issues

Join the Conversation

Trending Now on
ACCCBuzz Blog

Recently Heard on
CANCER BUZZ Podcast